
Sign up to save your podcasts
Or


ESMO 2026 brought exciting developments in lung cancer, from antibody-drug conjugates (ADCs) and targeted therapies to immunotherapy and T-cell engagers. But how much of it will actually change clinical practice?In our first full episode of (Im)Partial Response, Alex Friedlaender and José Sandoval take a critical look at the latest lung cancer data, discussing OptiTROP-Lung06, SAFFRON, OptiTROP-Lung04, PANKU-Lung01, KRAScendo-1, DeLLphi-305 and PERSEE.Survival benefits, comparators, toxicity, and clinical relevance.The main question remains: What changes in our practice?Complete opinions on incomplete data.
Welcome to (Im)Partial Response!In this introductory episode, medical oncologists José Sandoval and Alex Friedlaender introduce themselves, explain why they decided to launch yet another oncology podcast, and discuss what listeners can expect.From major oncology congresses and potentially practice-changing trials to controversies and unanswered questions, we'll explore the evidence behind cancer care and what it actually means for clinical practice.Expect critical discussions, independent perspectives, occasional disagreements, and a healthy dose of humour.Because in oncology, the data are rarely complete—but the opinions certainly are.
From the publisher's feed